A venture capital firm that helps to build ‘breakthrough biotech companies’ has raised $350 million to support the next generation of game changers.

Atlas Venture has been investing in biotech startups for 20 years. The $350 million – Fund XI – will enable it to deliver on its mission of doing well by doing good.

Atlas partner, Jason Rhodes said: “We are excited to be working at the forefront of scientific innovation to develop novel therapies for patients. With exceptional entrepreneurs as our partners, we look forward to continuing to build companies that will shape the future of medicine.”